Search Results - "KEER, Harold"

Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs by Fang, Fang, Cardenas, Horacio, Huang, Hao, Jiang, Guanglong, Perkins, Susan M, Zhang, Chi, Keer, Harold N, Liu, Yunlong, Nephew, Kenneth P, Matei, Daniela

“…DNA methylation aberrations have been implicated in acquired resistance to platinum drugs in ovarian cancer. In this study, we elucidated an epigenetic…”
Get full text

An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations by Pulliam, Nicholas, Fang, Fang, Ozes, Ali R, Tang, Jessica, Adewuyi, Adeoluwa, Keer, Harold, Lyons, John, Baylin, Stephen B, Matei, Daniela, Nakshatri, Harikrishna, Rassool, Feyruz V, Miller, Kathy D, Nephew, Kenneth P

“…PARP inhibitors (PARPi) are primarily effective against BRCA1/2-mutated breast and ovarian cancers, but resistance due to reversion of mutated BRCA1/2 and…”
Get full text

Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients by Jahn, Ekaterina, Saadati, Maral, Fenaux, Pierre, Gobbi, Marco, Roboz, Gail J., Bullinger, Lars, Lutsik, Pavlo, Riedel, Anna, Plass, Christoph, Jahn, Nikolaus, Walter, Claudia, Holzmann, Karlheinz, Hao, Yong, Naim, Sue, Schreck, Nicholas, Krzykalla, Julia, Benner, Axel, Keer, Harold N., Azab, Mohammad, Döhner, Konstanze, Döhner, Hartmut

“…To characterize the genomic landscape and leukemogenic pathways of older, newly diagnosed, non-intensively treated patients with AML and to study the clinical…”
Get full text

Methylomic Signatures of High Grade Serous Ovarian Cancer by Cardenas, Horacio, Fang, Fang, Jiang, Guanglong, Perkins, Susan M., Zhang, Chi, Emerson, Robert E., Hutchins, George, Keer, Harold N., Liu, Yunlong, Matei, Daniela, Nephew, Kenneth

“…High-grade serous ovarian cancer (HGSOC) harbours aberrant epigenetic features, including DNA methylation. In this study we delineate pathways and networks…”
Get full text

Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck by Seiwert, Tanguy, Sarantopoulos, John, Kallender, Howard, McCallum, Stewart, Keer, Harold N., Blumenschein, George

“…Summary Background Foretinib is a small-molecule, oral multikinase inhibitor primarily targeting the mesenchymal epithelial transition (MET) factor receptor,…”
Get full text

Correction: Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients by Jahn, Ekaterina, Saadati, Maral, Fenaux, Pierre, Gobbi, Marco, Roboz, Gail J., Bullinger, Lars, Lutsik, Pavlo, Riedel, Anna, Plass, Christoph, Jahn, Nikolaus, Walter, Claudia, Holzmann, Karlheinz, Hao, Yong, Naim, Sue, Schreck, Nicholas, Krzykalla, Julia, Benner, Axel, Keer, Harold N., Azab, Mohammad, Döhner, Konstanze, Döhner, Hartmut

Get full text

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer by Shah, Manish A, Wainberg, Zev A, Catenacci, Daniel V T, Hochster, Howard S, Ford, James, Kunz, Pamela, Lee, Fa-Chyi, Kallender, Howard, Cecchi, Fabiola, Rabe, Daniel C, Keer, Harold, Martin, Anne-Marie, Liu, Yuan, Gagnon, Robert, Bonate, Peter, Liu, Li, Gilmer, Tona, Bottaro, Donald P

“…The receptors for hepatocyte and vascular endothelial cell growth factors (MET and VEGFR2, respectively) are critical oncogenic mediators in gastric…”
Get full text

Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial by Garcia-Manero, Guillermo, Roboz, Gail, Walsh, Katherine, Kantarjian, Hagop, Ritchie, Ellen, Kropf, Patricia, O'Connell, Casey, Tibes, Raoul, Lunin, Scott, Rosenblat, Todd, Yee, Karen, Stock, Wendy, Griffiths, Elizabeth, Mace, Joseph, Podoltsev, Nikolai, Berdeja, Jesus, Jabbour, Elias, Issa, Jean-Pierre J, Hao, Yong, Keer, Harold N, Azab, Mohammad, Savona, Michael R

“…Guadecitabine is a next-generation hypomethylating agent whose active metabolite decitabine has a longer in-vivo exposure time than intravenous decitabine…”
Get full text

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2 by EDER, Joseph Paul, SHAPIRO, Geoffrey I, MCCALLUM, Stewart, HEATH, Elisabeth I, BOERNER, Scott A, LORUSSO, Patricia M, APPLEMAN, Leonard J, ZHU, Andrew X, MILES, Dale, KEER, Harold, CANCILLA, Belinda, CHU, Felix, HITCHCOCK-BRYAN, Suzanne, SHERMAN, Laurie

“…Foretinib is an oral multikinase inhibitor targeting Met, RON, Axl, and vascular endothelial growth factor receptor. We conducted a phase I,…”
Get full text

Correction: A novel epigenetic modulating agent sensitizes pancreatic cells to a chemotherapy agent by Thakar, Manjusha, Hu, Yue, Morreale, Michael, Lerner, Lane, Lin, Wan Ying, Sen, Rupashree, Cai, Yi, Karunasena, Enusha, Thakar, Maya, Saggi, Soren, Keer, Harold, Ahuja, Nita

“…[This corrects the article DOI: 10.1371/journal.pone.0199130.]…”
Get full text

A novel epigenetic modulating agent sensitizes pancreatic cells to a chemotherapy agent by Thakar, Manjusha, Hu, Yue, Morreale, Michael, Lerner, Lane, Ying Lin, Wan, Sen, Rupashree, Cai, Yi, Karunasena, Enusha, Thakar, Maya, Saggi, Soren, Keer, Harold, Ahuja, Nita

“…Pancreatic ductal adenocarcinoma (PDAC) is expected to be the second leading cause of cancer mortality by 2030. PDAC remains resistant to the majority of…”
Get full text

Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer by Shah, Manish A., Wainberg, Zev A., Catenacci, Daniel V. T., Hochster, Howard S., Ford, James, Kunz, Pamela, Lee, Fa-Chyi, Kallender, Howard, Cecchi, Fabiola, Rabe, Daniel C., Keer, Harold, Martin, Anne-Marie, Liu, Yuan, Gagnon, Robert, Bonate, Peter, Liu, Li, Gilmer, Tona, Bottaro, Donald P.

“…[This corrects the article DOI: 10.1371/journal.pone.0054014.]…”
Get full text

PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH‐RISK MYELODYSPLASTIC SYNDROMES (MDS) by Zeidan, Amer M., Mosher, Karen, Souza, Sonia, Mirakhur, Beloo, Keer, Harold, Taylor, Jason

Get full text

Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878) by Riess, Jonathan W, Reckamp, Karen L, Frankel, Paul, Longmate, Jeffrey, Kelly, Karen A, Gandara, David R, Weipert, Caroline M, Raymond, Victoria M, Keer, Harold N, Mack, Philip C, Newman, Edward M, Lara, Primo N

“…Onalespib is a novel heat shock protein 90 inhibitor (HSP90i). Previous preclinical and clinical studies with HSP90i have demonstrated activity in EGFR-mutant…”
Get full text

Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer by Shah, Manish A, Wainberg, Zev A, Catenacci, Daniel V T, Hochster, Howard S, Ford, James, Kunz, Pamela, Lee, Fa-Chyi, Kallender, Howard, Cecchi, Fabiola, Rabe, Daniel C, Keer, Harold, Martin, Anne-Marie, Liu, Yuan, Gagnon, Robert, Bonate, Peter, Liu, Li, Gilmer, Tona, Bottaro, Donald P

“…[This corrects the article DOI: 10.1371/journal.pone.0054014.]…”
Get full text

Real‐world study of the use of azacitidine in myelodysplasia in Australia by Enjeti, Anoop, Ashraf, Asma, Caillet, Vincent, Alam, Arif, Silar, Jonathan, Keer, Harold, Castaldi, Francesco, Paine, Taleisha

“…Hypomethylating agents are the most widely used upfront therapy for patients with myelodysplastic syndrome (MDS) who are not suitable for hematopoietic stem…”
Get full text

Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study by Garcia-Manero, Guillermo, McCloskey, James, Griffiths, Elizabeth A, Yee, Karen W L, Zeidan, Amer M, Al-Kali, Aref, Deeg, H Joachim, Patel, Prapti A, Sabloff, Mitchell, Keating, Mary-Margaret, Zhu, Nancy, Gabrail, Nashat Y, Fazal, Salman, Maly, Joseph, Odenike, Olatoyosi, Kantarjian, Hagop, DeZern, Amy E, O’Connell, Casey L, Roboz, Gail J, Busque, Lambert, Buckstein, Rena, Amin, Harshad, Randhawa, Jasleen, Leber, Brian, Shastri, Aditi, Dao, Kim-Hien, Oganesian, Aram, Hao, Yong, Keer, Harold N, Azab, Mohammad, Savona, Michael R

“…The DNA methyltransferase inhibitors azacitidine and decitabine for individuals with myelodysplastic syndromes or chronic myelomonocytic leukaemia are…”
Get full text

Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial by Roboz, Gail J., Sanz, Guillermo, Griffiths, Elizabeth A., Yee, Karen, Kantarjian, Hagop, Récher, Christian, Byrne, Michael T., Patkowska, Elżbieta, Kim, Hee-Je, Thomas, Xavier, Moors, Ine, Stock, Wendy, Illés, Árpád, Fenaux, Pierre, Miyazaki, Yasushi, Yamauchi, Takahiro, O'Connell, Casey L., Hao, Yong, Keer, Harold N., Azab, Mohammad, Döhner, Hartmut

“…•There was no clear survival benefit for guadecitabine over standard-of-care in patients with relapsed/refractory AML.•Guadecitabine produced higher clinical…”
Get full text

PB2358: PHASE 1‐2 STUDY OF THE SAFETY, PK, PD, AND PRELIMINARY ACTIVITY OF TOLINAPANT IN COMBINATION WITH ORAL DECITABINE/CEDAZURIDINE AND ORAL DECITABINE/CEDAZURIDINE ALONE IN SUBJECTS WITH R/R PTCL by Shortt, Jake, Poligone, Brian, Ribrag, Vincent, Zinzani, Pier Luigi, El‐Sharkawi, Dima, Walewski, Jan, Prica, Anca, Wilson, Laksmi, Souza, Sonia, Keer, Harold, Taylor, Jason, Marchi, Enrica

Get full text

Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study by Fenaux, Pierre, Gobbi, Marco, Kropf, Patricia L., Issa, Jean-Pierre J., Roboz, Gail J., Mayer, Jiri, Krauter, Jürgen, Robak, Tadeusz, Kantarjian, Hagop, Novak, Jan, Jedrzejczak, W. W., Thomas, Xavier, Ojeda-Uribe, Mario, Miyazaki, Yasushi, Min, Yoo Hong, Yeh, Su-Peng, Brandwein, Joseph, Gercheva-Kyuchukova, Liana, Demeter, Judit, Griffiths, Elizabeth, Yee, Karen, Döhner, Konstanze, Hao, Yong, Keer, Harold, Azab, Mohammad, Döhner, Hartmut

“…•No significant differences in complete response, survival, or overall grade ≥3 AEs were observed between guadecitabine and TC. [Display omitted] This phase 3…”
Get full text